X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. REDDYS LAB - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. REDDYS LAB FRESENIUS KABI ONCO./
DR. REDDYS LAB
 
P/E (TTM) x 22.1 26.0 85.0% View Chart
P/BV x 3.1 3.2 97.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   DR. REDDYS LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB
Mar-18
FRESENIUS KABI ONCO./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1762,788 6.3%   
Low Rs791,902 4.1%   
Sales per share (Unadj.) Rs37.7860.8 4.4%  
Earnings per share (Unadj.) Rs5.157.1 8.9%  
Cash flow per share (Unadj.) Rs6.7122.0 5.5%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5757.7 5.6%  
Shares outstanding (eoy) m158.23165.91 95.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.7 124.0%   
Avg P/E ratio x25.041.1 60.8%  
P/CF ratio (eoy) x18.919.2 98.5%  
Price / Book Value ratio x3.03.1 96.7%  
Dividend payout %035.0 0.0%   
Avg Mkt Cap Rs m20,135389,034 5.2%   
No. of employees `0001.223.5 4.9%   
Total wages/salary Rs m70332,149 2.2%   
Avg. sales/employee Rs Th5,176.26,070.8 85.3%   
Avg. wages/employee Rs Th610.41,366.6 44.7%   
Avg. net profit/employee Rs Th699.6402.5 173.8%   
INCOME DATA
Net Sales Rs m5,963142,810 4.2%  
Other income Rs m181,552 1.2%   
Total revenues Rs m5,981144,362 4.1%   
Gross profit Rs m1,43023,512 6.1%  
Depreciation Rs m25810,772 2.4%   
Interest Rs m-26788 -3.3%   
Profit before tax Rs m1,21613,504 9.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3424,380 7.8%   
Profit after tax Rs m8069,468 8.5%  
Gross profit margin %24.016.5 145.7%  
Effective tax rate %28.132.4 86.7%   
Net profit margin %13.56.6 203.9%  
BALANCE SHEET DATA
Current assets Rs m5,102104,984 4.9%   
Current liabilities Rs m2,38568,938 3.5%   
Net working cap to sales %45.625.2 180.5%  
Current ratio x2.11.5 140.4%  
Inventory Days Days15074 201.8%  
Debtors Days Days113104 109.4%  
Net fixed assets Rs m5,148104,385 4.9%   
Share capital Rs m158830 19.1%   
"Free" reserves Rs m6,556124,886 5.2%   
Net worth Rs m6,732125,716 5.4%   
Long term debt Rs m95225,089 3.8%   
Total assets Rs m10,388225,443 4.6%  
Interest coverage x-45.818.1 -252.4%   
Debt to equity ratio x0.10.2 70.9%  
Sales to assets ratio x0.60.6 90.6%   
Return on assets %7.54.5 165.0%  
Return on equity %12.07.5 159.0%  
Return on capital %14.69.7 150.5%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29872,623 7.3%   
Fx outflow Rs m1,77218,916 9.4%   
Net fx Rs m3,52553,707 6.6%   
CASH FLOW
From Operations Rs m1,27418,030 7.1%  
From Investments Rs m-1,204-14,883 8.1%  
From Financial Activity Rs m-196-4,440 4.4%  
Net Cashflow Rs m-126-1,236 10.2%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 9.6 35.3 27.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   42,599 75,885 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - GLENMARK PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS